Cassava sciences announces patient enrollment update for phase 3 studies of simufilam for the treatment of alzheimer's disease

Austin, texas, feb. 08, 2023 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a clinical-stage biotechnology company, today announced an update on patient enrollment for its on-going phase 3 clinical studies of simufilam for the treatment of alzheimer's disease dementia. simufilam, an oral drug, is cassava sciences' proprietary lead drug candidate.
SAVA Ratings Summary
SAVA Quant Ranking